DA
ZBIO

DCF Advisers’s Zenas BioPharma ZBIO Stock Holding History

DCF Advisers’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$715K Buy
+28,184
New +$560K 0.13% 72

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

DCF Advisers's ZBIO Position: Q2 2026 in Review

DCF Advisers opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 28,184 shares worth $715K. The stake represents 0.13% of the portfolio and ranks #72 among its holdings.

145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • DCF Advisers held 28,184 shares of Zenas BioPharma worth $715K as of Q2 2026.
  • Zenas BioPharma was a new DCF Advisers position in Q2 2026.
  • Zenas BioPharma made up 0.13% of DCF Advisers's portfolio in Q2 2026, its #72 holding.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.